Myocardial Rac1 exhibits partial involvement in thyroxin-induced cardiomyocyte hypertrophy and its inhibition is not sufficient to improve cardiac dysfunction or contractile abnormalities in mouse papillary muscles

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 6, 2013, Pages 536-544

  Elnakish, Mohammad T ^a,b   Moldovan, Leni ^a,b   Khan, Mahmood ^a,b   Hassanain, Hamdy H ^a   Janssen, Paul M L ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cardiomyocyte hypertrophy; Papillary muscle; Pravastatin; Rac1; Thyroxin

Indexed keywords

PRAVASTATIN; RAC1 PROTEIN; THYROXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; HEART FUNCTION; HEART PAPILLARY MUSCLE; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; IN VIVO STUDY; INOTROPISM; ISOMETRICS; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAXATION TIME; TREATMENT DURATION;

ANIMALS; CARDIOMEGALY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART; HEART VENTRICLES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; NEUROPEPTIDES; PAPILLARY MUSCLES; PRAVASTATIN; RAC GTP-BINDING PROTEINS; THYROXINE;

EID: 84879883665     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31828d4b9d     Document Type: Article

References (57)

1. Kuzman JA, Vogelsang KA, Thomas TA, et al. L-thyroxine activates Akt signaling in the heart. J Mol Cell Cardiol. 2005;39: 251-258.
2. Kuzman JA, Thomas TA, Vogelsang KA, et al. Effects of induced hyperthyroidism in normal and cardiomyopathic hamsters. J Appl Physiol. 2005;99: 1428-1433.
3. Bergh JJ, Lin HY, Lansing L, et al. Integrin aVb3 contains a cell surface receptor site for thyroid hormone that is linked to activation of MAPK and induction of angiogenesis. Endocrinology. 2005;146: 2864-2871.
4. Kenessey A, Ojamaa K. Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways. J Biol Chem. 2006;281: 20666-20672.
5. Kuzman JA, O'Connell TD, Gerdes AM. Rapamycin prevents thyroid hormone-induced cardiac hypertrophy. Endocrinology. 2007;148:3477- 3484.
6. Kobori H, Ichihara A, Suzuki H, et al. Role of the renin-angiotensin system in cardiac hypertrophy induced in rats by hyperthyroidism. Am J Physiol. 1997;273:H593-H599.
7. Kobori H, Ichihara A, Miyashita Y, et al. Local renin-angiotensin system contributes to hyperthyroidism-induced cardiac hypertrophy. J Endocrinol. 1999;160: 43-47.
8. Kinugawa K, Yonekura K, Ribeiro RC, et al. Regulation of thyroid hormone receptor isoforms in physiological and pathological cardiac hypertrophy. Circ Res. 2001;89: 591-598.
9. Wang B, Ouyang J, Xia Z. Effects of triiodo-thyronine on angiotensininduced cardiomyocyte hypertrophy: reversal of increased a-myosin heavy chain gene expression. Can J Physiol Pharmacol. 2006;84: 935-941.
10. Klein I, Hong C. Effects of thyroid hormone on cardiac size and myosin content of the heterotopically transplanted rat heart. J Clin Invest. 1986; 77: 1694-1698.
11. Korecky B, Zak R, Schwartz K, et al. Role of thyroid hormone in regulation of isomyosin composition, contractility, and size of heterotopically isotransplanted rat heart. Circ Res. 1987;60: 824-830.
12. Satoh M, Ogita H, Takeshita K, et al. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A. 2006; 103: 7432-7437.
13. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003;108: 1567-1574.
14. Hassanain HH, Gregg D, Marcelo ML, et al. Hypertension caused by transgenic overexpression of Rac1. Antioxid Redox Signal. 2007;9: 91-100.
15. Samuel MS, Lourenco FC, Olson MF. K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One. 2011;6:e17143.
16. Elnakish MT, Awad MM, Hassona MD, et al. Cardiac remodeling caused by transgenic over-expression of a corn Rac gene. Am J Physiol Heart Circ Physiol. 2011;301:H868-H880.
17. Elnakish MT, Hassona MD, Alhaj MA, et al. Rac-induced left ventricular dilation in thyroxin-treated ZmRacD transgenic mice: role of cardiomyocyte apoptosis and myocardial fibrosis. PLoS One. 2012;7:e42500.
18. Elnakish MT, Hassanain HH, Janssen PM. Vascular remodeling-associated hypertension leads to left ventricular hypertrophy and contractile dysfunction in profilin-1 transgenic mice. J Cardiovasc Pharmacol. 2012;60: 544-552.
19. Janssen PML, Hunter WC. Force, not sarcomere length, correlates with prolongation of isosarcometric contraction. Am J Physiol Heart Circ Physiol. 1995;269(pt 2):H676-H685.
20. Janssen PML, Hiranandani N, Mays TA, et al. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol. 2005;289:H2373-H2378.
21. Rodriguez EK, Hunter WC, Royce MJ, et al. A method to reconstruct myocardial sarcomere lengths and orientations at transmural sites in beating canine hearts. Am J Physiol Heart Circ Physiol. 1992;263 (pt 2):H293-H306.
22. Frank O. Zur dynamik des Herzmuskels. Z Biol. 1895;32: 370-447.
23. Starling EH. The Lineacre Lecture on the Law of the Heart. London, United Kingdom: Longman Greens; 1918.
24. Bowditch HP. Ueber die eigenthuemlichkeiten der reizbarkeit, welche die muskelfasern des herzens zeigen. Ber Sachs Ges (Akad) Wiss. 1871;23: 652-689.
25. Riaz K, Forker AD, Isley WL, et al. Hyperthyroidism: a "curable" cause of congestive heart failure - three case reports and a review of the literature. Congest Heart Fail. 2003;9: 40-46.
26. García del Rio C, Moreno MR, Osuna A, et al. Role of the renin-angiotensin system in the development of thyroxine-induced hypertension. Eur J Endocrinol. 1997;136: 656-660.
27. Seppet EK, Eimre MA, Kallikorm AP. Modulation of stimulation frequency responses and calcium dependency of functional parameters in hyperthyroid rat ventricular papillary muscles. Can J Physiol Pharmacol. 1990;68: 1214-1220.
28. Smitherman TC, Johnson RS, Taubert K, et al. Acute thyrotoxicosis in the rabbit: changes in cardiac myosin, contractility, and ultrastructure. Biochem Med. 1979;21: 277-298.
29. Handberg GM, Ishac EJ, Pennefather JN. Influence of altered thyroid state on the interval-strength relationship of paced left atria of rats. J Cardiovasc Pharmacol. 1984;6: 936-942.
30. Holubarsch C, Holubarsch T, Jacob R, et al. Passive elastic properties of myocardium in different muscles and stages at hypertrophy: a study comparing mechanical, chemical and morphometric parameters. Perspect Cardiovasc Res. 1983;7: 323-336.
31. Taylor RR. Contractile properties of cardiac muscle in hyperthyroidism. Analysis of behavior of hyperthyroid cat papillary muscle in vitro relevant to thyrotoxic heart disease. Circ Res. 1970;27: 539-549.
32. Takács IE, Szabó J, Nosztray K, et al. Alterations of contractility and sarcoplasmic reticulum function of rat heart in experimental hypo- and hyperthyroidism. Gen Physiol Biophys. 1985;4: 271-278.
33. Buccino RA, Spann JF Jr, Pool PE, et al. Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest. 1967;46: 1669-1682.
34. Sharp NA, Neel DS, Parsons RL. Influence of thyroid hormone levels on the electrical and mechanical properties of rabbit papillary muscle. J Mol Cell Cardiol. 1985;17: 119-132.
35. Wei JY, Spurgeon HA, Lakatta EG. Electromechanical responsiveness of hyperthyroid cardiac muscle to beta-adrenergic stimulation. Am J Physiol. 1982;243:E114-E122.
36. Janssen PML, Periasamy M. Determinants of frequency-dependent contraction and relaxation of mammalian myocardium. J Mol Cell Cardiol. 2007;43: 523-531.
37. Redel A, Baumgartner W, Golenhofen K, et al. Mechanical activity and force-frequency relationship of isolated mouse papillary muscle: effects of extracellular calcium concentration, temperature and contraction type. Pflugers Arch. 2002;445: 297-304.
38. Strauer BE, Scherpe A. Experimental hyperthyroidism: III. Contractile responses to propranolol of the intact heart and of the isolated ventricular myocardium. Basic Res Cardiol. 1975;70: 237-245.
39. Hashimoto H, Nakashima M. Influence of thyroid hormone on the positive inotropic effects mediated by a- and b-adrenoceptors in isolated guinea pig atria and rabbit papillary muscles. Eur J Pharmacol. 1978; 50: 337-347.
40. Levey GS, Skelton CL, Epstein SE. Influence of hyperthyroidism on the effects of norepinephrine on myocardial adenyl cyclase activity and contractile state. Endocrinology. 1969;85: 1004-1009.
41. Benfey BG, Varma DR. Cardiac and vascular effects of sympathomimetic drugs after administration of tri-iodothyronine and reserpine. Br J Pharmacol. 1963;21: 174-181.
42. Crozatier B, Su JB, Corsin A, Bouanani N el-H. Species differences in myocardial b-adrenergic receptor regulation in response to hyperthyroidism. Circ Res. 1991;69: 1234-1243.
43. Hacontrolhorn MH, Gengo P, Wei XY, et al. Effect of thyroid status on b-adrenoceptors and calcium channels in rat cardiac and vascular tissue. Naunyn Schmiedebergs Arch Pharmacol. 1988;337: 539-544.
44. Rashid M, Tawara S, Fukumoto Y, et al. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J. 2009;73: 361-370.
45. Xu Z, Okamoto H, Akino M, et al. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol. 2008;51: 62-70.
46. Bezerra DG, Mandarim-de-Lacerda CA. Beneficial effect of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruli loss in spontaneously hypertensive rats. Clin Sci (Lond). 2005; 108: 349-355.
47. Lee TM, Lin MS, Chou TF, et al. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289:H220-H227.
48. Papparella I, Ceolotto G, Montemurro D, et al. Green tea attenuates angiotensin II-induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/epidermal grocontrolh factor receptor/Akt signaling pathway. J Nutr. 2008;138: 1596-1601.
49. Vargas F, Moreno JM, Rodríguez-Gómez I, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol. 2006; 154: 197-212.
50. Kassan M, Montero MJ, Sevilla MA. Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats. Br J Pharmacol. 2009;158: 541-547.
51. Vargas F, Atucha N, Sabio JM, et al. Pressure-diuresis-natriuresis response in hyper- and hypothyroid rats. Clin Sci (Lond). 1994;87: 323-328.
52. Shibata S, Nagase M, Yoshida S, et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14: 1370-1376.
53. Shibata S, Mu S, Kawarazaki H, et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptordependent pathway. J Clin Invest. 2011;12: 3233-3243.
54. Kido M, Ando K, Oba S, et al. Renoprotective effect of pravastatin in salt-loaded Dahl salt-sensitive rats. Hypertens Res. 2005;28: 1009-1015.
55. Moreno JM, Rodríguez Gómez I, Wangensteen R, et al. Cardiac and renal antioxidant enzymes and effects of tempol in hyperthyroid rats. Am J Physiol Endocrinol Metab. 2005;289:E776-E783.
56. Wang M, Zhang J, Walker SJ, et al. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol. 2010;48: 765-772.
57. Hu LW, Benvenuti LA, Liberti EA, et al. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol. 2003;285:R1473-R1480.